This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ceapro 관리

관리 기준 확인 3/4

Ceapro's CEO는 Gilles Gagnon, Jan2008 에 임명되었습니다 의 임기는 16.42 년입니다. 총 연간 보상은 CA$ 560.00K, 85.7% 로 구성됩니다. 85.7% 급여 및 14.3% 보너스(회사 주식 및 옵션 포함). 는 CA$ 335.03K 가치에 해당하는 회사 주식의 1.9% 직접 소유합니다. 335.03K. 경영진과 이사회의 평균 재임 기간은 각각 9.1 년과 9.2 년입니다.

주요 정보

Gilles Gagnon

최고 경영자

CA$560.0k

총 보상

CEO 급여 비율	85.7%
CEO 임기	16.4yrs
CEO 소유권	1.9%
경영진 평균 재임 기간	9.1yrs
이사회 평균 재임 기간	9.2yrs

최근 관리 업데이트

Recent updates

Ceapro Inc. (CVE:CZO) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Nov 28

CEO 보상 분석

Gilles Gagnon 의 보수는 Ceapro 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	n/a	n/a	-CA$5m
Sep 30 2023	n/a	n/a	-CA$3m
Jun 30 2023	n/a	n/a	-CA$759k
Mar 31 2023	n/a	n/a	CA$2m
Dec 31 2022	CA$560k	CA$480k	CA$4m
Sep 30 2022	n/a	n/a	CA$6m
Jun 30 2022	n/a	n/a	CA$6m
Mar 31 2022	n/a	n/a	CA$5m
Dec 31 2021	CA$560k	CA$480k	CA$3m
Sep 30 2021	n/a	n/a	CA$2m
Jun 30 2021	n/a	n/a	CA$844k
Mar 31 2021	n/a	n/a	CA$1m
Dec 31 2020	CA$507k	CA$480k	CA$2m
Sep 30 2020	n/a	n/a	CA$3m
Jun 30 2020	n/a	n/a	CA$2m
Mar 31 2020	n/a	n/a	CA$630k
Dec 31 2019	CA$518k	CA$480k	-CA$1m
Sep 30 2019	n/a	n/a	-CA$855k
Jun 30 2019	n/a	n/a	-CA$1m
Mar 31 2019	n/a	n/a	-CA$657k
Dec 31 2018	CA$555k	CA$480k	-CA$316k
Sep 30 2018	n/a	n/a	-CA$2m
Jun 30 2018	n/a	n/a	-CA$2m
Mar 31 2018	n/a	n/a	-CA$1m
Dec 31 2017	CA$1m	CA$480k	-CA$958k

보상 대 시장: Gilles 의 총 보상 ($USD 410.93K )은 Canadian 시장( $USD 175.07K ).

보상과 수익: Gilles 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Gilles Gagnon (70 yo)

16.4yrs

테뉴어

CA$560,000

보상

Mr. Gilles R. Gagnon, M.Sc. MBA, ICD D, serves as Independent Director of Aeterna Zentaris Inc. since January 1, 2020. He serves as the President of Spectrum Pharma Canada Inc. (Spectrum Canada).Mr. Gagno...

리더십 팀

이름	위치	테뉴어	보상	소유권
Gilles Gagnon	CEO, President & Director	16.4yrs	CA$560.00k	1.9% CA$ 335.0k
Stacy Prefontaine	CFO & Corporate Secretary	9.1yrs	CA$232.99k	0.042% CA$ 7.3k
Bernhard Seifried	Senior Director of Research & Technology	no data	데이터 없음	데이터 없음
Michel Regnier	Senior Vice President of Technical Operations	1.1yrs	데이터 없음	데이터 없음

9.1yrs

평균 재임 기간

경험이 풍부한 관리: CZO 의 관리팀은 노련하고 경험 (평균 재직 기간 9.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gilles Gagnon	CEO, President & Director	16.8yrs	CA$560.00k	1.9% CA$ 335.0k
Genevieve Foster	Independent Director	2.2yrs	CA$92.38k	데이터 없음
William Li	Independent Director	9.6yrs	CA$59.57k	0.13% CA$ 22.9k
Ronald Miller	Independent Chairman	2.1yrs	CA$96.06k	데이터 없음
Ulrich Kosciessa	Independent Director	9.2yrs	CA$57.79k	0.10% CA$ 17.6k

9.2yrs

평균 재임 기간

경험이 풍부한 이사회: CZO 의 이사회는 경험(평균 재직 기간 9.2 년)으로 간주됩니다.

This company is no longer active

Ceapro 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Ceapro Inc. Announces Resignation of Glenn Rourke as A Director

Ceapro Inc. Appoints Sigrun Watson as Chief Revenue Officer

Ceapro Inc. Appoints Ronnie Miller as Chairman of the Board and Genevieve Foster Will Chair the Audit Committee

High number of new directors

Insufficient new directors

Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors

Recent updates

Ceapro Inc. Ordinary Shares to Be Deleted from OTC Equity

Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction.

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Third quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.011 profit in 3Q 2022)

Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.021 profit in 2Q 2022)

The Returns At Ceapro (CVE:CZO) Aren't Growing

Ceapro Inc. Announces Resignation of Glenn Rourke as A Director

First quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.026 profit in 1Q 2022)

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

Full year 2022 earnings released: EPS: CA$0.056 (vs CA$0.037 in FY 2021)

Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2A Human Clinical Trial Assessing Avenanthramide Tablets

Third quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.011 in 3Q 2021)

Ceapro Inc. Launches Next Phase of Scale Up for Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets

Returns At Ceapro (CVE:CZO) Are On The Way Up

Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers

Second quarter 2022 earnings released: EPS: CA$0.021 (vs CA$0.009 in 2Q 2021)

Ceapro Inc. Appoints Sigrun Watson as Chief Revenue Officer

Ceapro's (CVE:CZO) Returns Have Hit A Wall

Ceapro Inc. Appoints Ronnie Miller as Chairman of the Board and Genevieve Foster Will Chair the Audit Committee

High number of new directors

First quarter 2022 earnings released: EPS: CA$0.026 (vs CA$0.007 in 1Q 2021)

Insufficient new directors

Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors

Full year 2021 earnings released: EPS: CA$0.037 (vs CA$0.024 in FY 2020)

Ceapro Inc., Annual General Meeting, Jun 01, 2022

Ceapro Appoints Ronnie Miller to its Board of Directors

Ceapro Appoints Ronnie Miller to its Board of Directors

Ceapro (CVE:CZO) Will Want To Turn Around Its Return Trends

Third quarter 2021 earnings released: EPS CA$0.011 (vs CA$0.002 in 3Q 2020)

Second quarter 2021 earnings released

Be Wary Of Ceapro (CVE:CZO) And Its Returns On Capital

Ceapro Inc. Announces Completion of Patient Enrollment in Clinical Study Evaluating Beta Glucan as A Cholesterol-Lowering Agent

Ceapro's (CVE:CZO) Robust Earnings Are Supported By Other Strong Factors

First quarter 2021 earnings released

Estimating The Fair Value Of Ceapro Inc. (CVE:CZO)

Full year 2020 earnings released

New 90-day low: CA$0.63

Will Ceapro (CVE:CZO) Multiply In Value Going Forward?

Is It Too Late To Consider Buying Ceapro Inc. (CVE:CZO)?

New 90-day high: CA$0.79

Estimating The Fair Value Of Ceapro Inc. (CVE:CZO)

Ceapro Inc. (CVE:CZO) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

New 90-day high - CA$0.84

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간